Time Constraints of Zyprexa Lawsuits

Time Constraints of Zyprexa Lawsuits

Zyprexa is currently the most popular antipsychotic medication in the United States, but more and more information about potentially damaging and sometimes deadly side effects continue to emerge. If you have been prescribed Zyprexa and have since developed diabetes, pancreatitis, hyperglycemia, or a diabetes-induced heart attack, you should contact an experienced personal injury attorney as soon as possible.

Time is of the essence when it comes to filing a successful lawsuit against the makers of Zyprexa for the dangerous side effect that you've suffered. Eli Lilly and other large pharmaceutical companies stand to take a huge loss in the face of each successful case against them, so they bank on valuable time elapsing before a victim consults an attorney. Since states have varying statute of limitations restraints that limit the window of opportunity to file a claim against the company, waiting too long can terminate the case before it even begins and leave the innocent victim empty-handed.

Large pharmaceutical corporations and insurance companies are inevitably working to minimize their own liability in defective drugs and product claims in order to stay hugely profitable and to cultivate new business. It's up to victims like yourself to take a stand against suffering from unnecessary side effects by filing a claim before the statutes of limitations expire. Contact our lawyers today for a free case review.



       
  • - -
  • By clicking the "Submit" button below, you agree that law firms you are matched with may contact you by telephone even if you are on a federal or state Do Not Call registry. Up to 10 law firms may respond to your request within approximately 2 weeks. In some cases 3 or more firms may respond to your request after 30 days. Use of this site is subject to our Terms of Use.

Sitemap

Website Design & Web Positioning by Wise Law Group

Copyright ©2012- All rights reserved | Terms of Use

[an error occurred while processing this directive]